Clinical trials: Asthma Patients
Asthma
A Study of RO5036505 in Patients With Moderate to Severe Asthma
This randomized, double-blind, placebo-controlled study will evaluate the efficacy, safety and tolerability of RO5036505 in patients with inadequately controlled moderate to severe asthma.
- Trial name
- NCT00967590
- Testing
- RO5036505
- Where
- 16 sites in United States, United Kingdom
- Sponsor
- Hoffmann-La Roche
Severe Asthma
Open-label Study to Assess Reduction of Background Asthma Medication While Sustaining Asthma Control and Clinical Remission With Tezepelumab in Patients 12-80yrs With Severe Asthma.
The objective of this study is to assess the potential for tezepelumab-treated patients (subcutaneous administration) to reduce maintenance therapy without loss of asthma control in adolescent and adults with severe asthma..
- Trial name
- ARRIVAL (NCT06473779)
- Testing
- Tezepelumab, Budesonide/formoterol, Albuterol/budesonide (AIRSUPRA®)
- Where
- 70 sites in United States, Argentina and 10 more
- Volunteers
- 310 people
- Sponsor
- AstraZeneca
Healthy, Asthma
Multiple Rising Dose Study of BI 144807 Powder in Bottle in Mild Asthmatic Patients
In this trial the safety, tolerability, pharmacokinetics and exploratory pharmacodynamics of multiple dose administration of BI 144807 will be investigated in otherwise healthy, controlled asthmatic patients
- Trial name
- NCT01651598
- Testing
- BI 144807
- Where
- United Kingdom
- Volunteers
- 57 people
- Sponsor
- Boehringer Ingelheim
Healthy Volunteers, Asthma
A First Time in Human Study of PIN201104 in Healthy Volunteers and Patients With Asthma
The purpose of this study is to assess the safety, tolerability and pharmacokinetics of different single and repeat doses of PIN201104 in healthy volunteers and in patients with asthma.
- Trial name
- NCT03058458
- Testing
- PIN201104
- Where
- United Kingdom
- Volunteers
- 94 people, healthy volunteers welcome
- Sponsor
- Peptinnovate
Asthma
Study on the Effects of an AMP Challenge on Asthmatic Patients Following Treatment With Fluticasone Propionate
Inhaling AMP causes an inflammatory response in the lung. This study will investigate whether 5-days of treatment with fluticasone propionate protects the lung from responding to the AMP in this way.
- Trial name
- NCT00400855
- Testing
- Fluticasone propionate
- Where
- 2 sites in New Zealand
- Volunteers
- 49 people
- Sponsor
- GlaxoSmithKline
Bronchial Asthma
A Study to Evaluate the Efficacy and Safety of HSK31858 Tablets in Patients with Bronchial Asthma
This is a phase II, randomised, double-blind, placebo-controlled, multicenter study to assess the efficacy and safety of HSK31858 in patients with bronchial asthma
- Trial name
- NCT06637254
- Testing
- HSK31858
- Where
- China
- Volunteers
- 219 people
- Sponsor
- Haisco Pharmaceutical Group Co., Ltd.
Eosinophilic Asthma
A Study to Evaluate the Efficacy and Safety of Reslizumab in Patients With Eosinophilic Asthma
The primary objective of this study is to determine whether reslizumab is more effective than placebo in reducing the number of clinical asthma exacerbations (CAEs) in patients with eosinophilic asthma.
- Trial name
- NCT01285323
- Testing
- Reslizumab
- Where
- 104 sites in United States, Argentina and 13 more
- Volunteers
- 464 people
- Sponsor
- Teva Branded Pharmaceutical Products R&D, Inc.
Severe Eosinophilic Asthma
Patient Reported Outcomes in Adults With Severe Eosinophilic Asthma on Benralizumab.
This study will generate patient reported outcomes (PROs) associated with the use of benralizumab as treatment for severe eosinophilic asthma.
- Trial name
- POWER (NCT03833141)
- Testing
- Survey Administration
- Where
- 20 sites in Canada
- Volunteers
- 170 people
- Sponsor
- AstraZeneca
Rhinoconjunctivitis
Multicenter Trial of Immunotherapy With House Dust Mite Allergoid
Multicenter Immunotherapy House Dust Mite Allergoid
- Trial name
- ACRI (NCT00540631)
- Testing
- specific immunotherapy with Acaroid, subcutaneously, Up-titration till strength B 0.6 mL (6000 TU)
- Where
- Germany
- Volunteers
- 108 people
- Sponsor
- Allergopharma GmbH & Co. KG
Asthma
A Study to Evaluate the Efficacy and Safety of Meptin® Swinghaler® and Ventolin® MDI in Stable Asthma Patients
This is an open-label, randomized, cross-over, active-controlled study to evaluate the efficacy and safety effects using Meptin® Swinghaler and Ventolin® MDI in stable asthma patients.
- Trial name
- NCT01076322
- Testing
- Meptin® Swinghaler, Ventolin® MDI
- Where
- Taiwan
- Volunteers
- 17 people
- Sponsor
- Taiwan Otsuka Pharm. Co., Ltd
Asthma
Efficacy, Safety and Pharmacokinetics of QAV680 Versus Placebo in Patients With Asthma
This study will assess the safety and efficacy of QAV680 in patients with mild to moderate asthma
- Trial name
- NCT01103037
- Testing
- QAV680
- Where
- 7 sites in United States, Germany and 1 more
- Volunteers
- 8 people
- Sponsor
- Novartis Pharmaceuticals
Asthma
Efficacy of Ciclesonide on Small Airways in Patients With Stable Asthma (18 to 60 y) (BY9010/M1-131)
The aim of this study is to evaluate the involvement of small airways in asthma, as determined by bronchial challenges, CT-scanning, and cellular markers of inflammation. Ciclesonide will be inhaled at one dose level once daily.
- Trial name
- NCT00163345
- Testing
- Ciclesonide
- Where
- Netherlands
- Volunteers
- 20 people
- Sponsor
- AstraZeneca
Asthma
Pharmacokinetic and Pharmacodynamic Profiles of Albuterol Spiromax® and ProAir® Hydrofluoroalkane (HFA) in Pediatric Patients With Asthma
The primary objective of this study is to compare the pharmacokinetic (PK) profiles of Albuterol Spiromax® and ProAir HFA after administration of a single inhaled dose of 180 mcg albuterol base from each product.
- Trial name
- NCT01844401
- Testing
- Albuterol Spiromax®, ProAir® HFA
- Where
- United States
- Volunteers
- 15 people
- Sponsor
- Teva Branded Pharmaceutical Products R&D, Inc.
Asthma
The Effect of BIIL 284 BS on Induced-sputum Variables in Patients With Bronchial Asthma
Study to evaluate the anti-inflammatory effect of BIIL 284 BS compared with placebo in patients with asthma
- Trial name
- NCT02249312
- Testing
- BIIL 284 BS
- Volunteers
- 38 people
- Sponsor
- Boehringer Ingelheim
Asthma
Real Life Effectiveness in Patients With Not Optimally Controlled Asthma
A non-interventional study to explore actual asthma control status in real-life environment and to observe the efficacy after stepped-up to Symbicort SMART or various identical regimens.
- Trial name
- NCT00784953
- Where
- 6 sites in Taiwan
- Volunteers
- 842 people
- Sponsor
- AstraZeneca
Asthma
Pediatric Ease of Use ELLIPTA Items
A range of devices has been developed to administer inhaled therapy for asthma, including dry powder inhaler (DPI) devices. ELLIPTA is a DPI that is preloaded with a drug therapy to treat asthmatic subjects.
- Trial name
- NCT03315572
- Testing
- Interviewer administered version of ease of use items, Self-administered version of ease of use items, Caregiver version of ease of use items
- Where
- 2 sites in United States
- Volunteers
- 28 people
- Sponsor
- GlaxoSmithKline
Asthma, Chronic Obstructive Pulmonary Disease
Inspiratory Flow Parameters of Easyhaler and Diskus Inhalers (SALIF)
The purpose of this study is to characterise inspiratory flow parameters across 2 Easyhaler® (EH) inhaler versions and Diskus® inhaler in patients with asthma (including children, adults, and the elderly) and in patients with…
- Trial name
- SALIF (NCT01424137)
- Testing
- Easyhaler type A, Easyhaler type B, Diskus inhaler
- Where
- 5 sites in Estonia, Finland
- Volunteers
- 227 people
- Sponsor
- Orion Corporation, Orion Pharma
Asthma
Efficacy and Safety of Different Doses of Indacaterol
This study compared the 14-day bronchodilator efficacy of indacaterol with that of placebo and salmeterol
- Trial name
- NCT01079130
- Testing
- Indacaterol, Salmeterol
- Where
- 71 sites in United States
- Volunteers
- 511 people
- Sponsor
- Novartis Pharmaceuticals
Asthma
Cross-Over Study of Subcutaneous Study Drug for the Treatment of Patients With Mild to Moderate Asthma
The objective of this study is to evaluate if single subcutaneous (SC) doses of PL-3994, administered to patients with asthma can achieve a clinically meaningful increase in pulmonary function (Forced Expiratory Volume in one…
- Trial name
- NCT01304628
- Testing
- PL-3994
- Where
- United States
- Sponsor
- Palatin Technologies, Inc
Severe Asthma
Characterization and Clinical Outcomes of Severe Asthma Patients in Israel Treated With Benralizumab (SAIL-B)
A retrospective, observational, one arm, single country study, using the computerized database of Maccabi Health Services (MHS).
- Trial name
- SAIL-B (NCT07218172)
- Where
- Israel
- Volunteers
- 197 people
- Sponsor
- AstraZeneca